XTL Biopharmaceuticals nominates Gilai Dolev as external director
XTLB•XTL Biopharmaceuticals nominated Gilai Dolev to replace resigning external director Iris Shapira Yalon, subject to shareholder approval. Dolev would serve an initial three-year term.
1. Director nomination
Iris Shapira Yalon submitted her resignation on October 12, 2026, citing personal reasons. Her departure takes effect when her successor is appointed or on November 20, 2026, whichever comes first. The board nominated Gilai Dolev on October 14, subject to shareholder approval.
